

## UNITED STATES PATENT AND-TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/755,325	01/05/2001	Ali Hemmati-Brivanlou	7529/1H460US2	7033
7:	590 . 03/20/2002			
DARBY & DARBY P.C.		EXAMINER		
805 Third Avenue New York, NY 10022			ZEMAN, ROBERT	
			ART UNIT	PAPER NUMBER
			1645	7
			DATE MAILED: 03/20/2002	/

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application Ma	Applicant/a)				
	Application No.	Applicant(s)				
Office Action Commence	09/755,325	HEMMATI-BRIVANLOU ET AL.				
Office Action Summary	Examiner	Art Unit				
	Robert A Zeman	1645				
The MAILING DATE of this communicated for Reply	ation appears on the cover sneet	with the correspondence address				
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNIC.  - Extensions of time may be available under the provisions of after SIX (6) MONTHS from the mailing date of this communical fit the period for reply specified above is less than thirty (30).  - If NO period for reply is specified above, the maximum statu.  - Failure to reply within the set or extended period for reply with any reply received by the Office later than three months after earned patent term adjustment. See 37 CFR 1.704(b).  Status	ATION.  37 CFR 1.136(a). In no event, however, may nication. days, a reply within the statutory minimum of tory period will apply and will expire SIX (6) M II. by statute, cause the application to become	r a reply be timely filed thirty (30) days will be considered timely. IONTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed	d on <u>05 January 2001</u> .					
2a) This action is <b>FINAL</b> . 2t	o) This action is non-final.					
3) Since this application is in condition f closed in accordance with the practic		natters, prosecution as to the merits is C.D. 11, 453 O.G. 213.				
Disposition of Claims						
4) Claim(s) 13-26 is/are pending in the application.						
4a) Of the above claim(s) is/are	withdrawn from consideration.					
5) Claim(s) is/are allowed.						
	6) Claim(s) is/are rejected.					
,	7) Claim(s) is/are objected to.					
8) Claim(s) <u>13-26</u> are subject to restriction <b>Application Papers</b>	on and/or election requirement.					
9) The specification is objected to by the	Fyaminer					
10) The drawing(s) filed on is/are: a		v the Examiner.				
Applicant may not request that any object						
11) The proposed drawing correction filed						
If approved, corrected drawings are requ		•				
12)☐ The oath or declaration is objected to b	y the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for	or foreign priority under 35 U.S.C	C. § 119(a)-(d) or (f).				
a) All b) Some * c) None of:						
1. Certified copies of the priority do	ocuments have been received.					
2. Certified copies of the priority do	ocuments have been received ir	Application No				
	tional Bureau (PCT Rule 17.2(a)					
14) Acknowledgment is made of a claim for	•					
a) ☐ The translation of the foreign lang 15)☐ Acknowledgment is made of a claim for	uage provisional application has	s been received.				
Attachment(s)	. and the property and the control					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-3) Information Disclosure Statement(s) (PTO-1449) Page	O-948) 5) Notice	ew Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO-152)				

Application/Control Number: 09/755,325

Art Unit: 1645

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 13-19, drawn to isolated eIF-4AIII proteins, proteolytic fragments and fusion proteins, classified in class 530, subclass 350.
- II. Claims 20-22, drawn to monoclonal antibodies, classified in class 350, subclass 587.1.
- III. Claims 23-26, drawn to methods of identifying potential drugs, classified in class435, subclass 70.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are separate and distinct from each other, as they comprise differing biochemical and physical entities having differing properties and uses. Invention I is drawn to proteins and protein fragments, whereas Invention II is drawn to antibodies.

Inventions I and II are separate and distinct from Invention III as the substances of Inventions I and II cannot be used in the methods of Invention III.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Art Unit: 1645

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A Zeman whose telephone number is (703) 308-7991. The examiner can normally be reached on M-Th 7:30 am - 5:00 pm and Alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Donna Wortman can be reached on (703) 308-1032. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

DONNAWORTMAN PRIMARY EXAMINER

Robert A. Zeman March 12, 2002